Hepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous HEV infection in developed countries.
Chronic HEV infection is now recognized, and in transplant recipients this may lead to cirrhosis and organ failure.
Dr Donnelly and colleagues from the United Kingdom detailed current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.
PubMed was searched for English language articles using the key words “hepatitis E”, “viral hepatitis”, “autochthonous infection”, “antiviral therapy”, “liver transplantation”, “acute”, “chronic”, “HEV”, “genotype”, “transmission” “food-borne”, “transfusion”. Additional relevant publications were identified from article reference lists.
|Ribavirin therapy is used to treat patients with chronic HEV infection|
|Alimentary Pharmacology & Therapeutics|
The team noted an increasing recognition of autochthonous HEV infection in Western countries, mainly associated with genotype 3.
Chronic HEV infection has been recognized since 2008, and in transplant recipients this may lead to cirrhosis and organ failure.
The researchers reported that modes of transmission include food-borne transmission, transfusion of blood products and solid organ transplantation.
Ribavirin therapy is used to treat patients with chronic HEV infection, but new therapies are required as there have been reports of treatment failure with ribavirin.
Dr Donnelly's team concludes, "Autochthonous HEV infection is a clinical issue with increasing burden."
"Future work should focus on increasing awareness of HEV infection in the developed world, emphasizing the need for clinicians to have a low threshold for HEV testing, particularly in immunosuppressed patients."
"Patients at potential risk of chronic HEV infection must also be educated and given advice regarding prevention of infection."